Quiver Bioscience Secures Strategic Investment From Porta Family
Quiver Bioscience announced a targeted strategic investment from the Porta family to fund its Argentina office and advance its antisense oligonucleotide program for Dup15q syndrome. The funding will support pre‑clinical safety studies and candidate selection on the path toward clinical development. Deal value was not disclosed.
Gilead to Acquire Tubulis for ~$5B
Gilead has entered into a definitive agreement to acquire Tubulis, an ADC research organization, for an upfront $3.15B plus up to $1.85B in contingent milestone payments, totaling roughly $5B. The acquisition will expand Gilead’s ADC capabilities and add next‑generation assets...
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B
Neurocrine Biosciences announced a $2.9 billion cash acquisition of Soleno Therapeutics, a Bay Area biotech known for its VYKAT XR therapy for Prader‑Willi syndrome. The deal gives Neurocrine its first metabolic‑disorder therapy and aims to accelerate its obesity drug pipeline. Soleno will...
Merck KGaA Completes Acquisition of JSR Life Sciences Chromatography Business
German chemicals and life sciences group Merck KGaA has completed its acquisition of the chromatography business of JSR Life Sciences, adding Protein A chromatography capabilities and a team of over 50 employees to its process solutions portfolio. The deal expands Merck's...
Biogen to Acquire Apellis Pharmaceuticals for $5.6B
Biogen announced on March 31, 2026 that it will acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, adding Apellis’ rare‑disease drugs Empaveli and Syfovre to its portfolio. The deal expands Biogen’s rare‑disease pipeline as its multiple‑sclerosis revenues decline.
Kyntra Bio Completes Sale of FibroGen China to AstraZeneca
Kyntra Bio announced the completion of the sale of its FibroGen China assets to AstraZeneca, enabling full repayment of its senior secured term loan and extending its cash runway into 2028.
Gilead Sciences to Acquire Ouro Medicines in over $2 Billion Buyout
Gilead Sciences announced it will acquire privately held biotech Ouro Medicines for more than $2 billion, adding the experimental antibody OM336 to its immunology pipeline. The deal expands Gilead’s portfolio of autoimmune therapies as it seeks growth beyond its HIV...
AstraZeneca Acquires FibroGen China From Kyntra Bio
Kyntra Bio completed the sale of its FibroGen China assets to AstraZeneca, enabling repayment of its senior secured term loan and extending its cash runway. The transaction was announced during Kyntra Bio's Q4 2025 earnings call on March 16, 2026.
Enodia Therapeutics Acquires Kezar Life Sciences' Sec61 Assets for Up to $127M
Enodia Therapeutics announced it has acquired the Sec61‑based discovery and development assets of Kezar Life Sciences. The transaction includes an upfront payment of $1 million and potential milestone payments up to $127 million, plus royalties, bolstering Enodia’s targeted protein degradation platform and...
Cognito Therapeutics Secures $105M Series C to Advance At‑Home Alzheimer’s Therapy
Cognito Therapeutics announced the closing of an oversubscribed $105 million Series C round led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation from Apollo Health Ventures and Benvolio Group. The funding will support a pivotal data readout, regulatory filing...
ASPR Invests in Antheia, Inc. To Boost Domestic Thebaine Production
The Administration for Strategic Preparedness and Response (ASPR) announced on March 5 that it will invest in Antheia, Inc., a Menlo Park‑based company, to produce thebaine domestically for pain management and opioid‑overdose reversal medications. The funding aims to reduce reliance on foreign...
Kairos Pharma Signs Binding Agreement to Acquire Exclusive Worldwide Rights to CL‑273 From Celyn Therapeutics
Kairos Pharma announced it has signed a binding agreement to acquire the exclusive worldwide rights to the AI‑designed pan‑EGFR inhibitor CL‑273 from Celyn Therapeutics, a biotech backed by OrbiMed and Torrey Pines Investment. The acquisition expands Kairos’s oncology pipeline and...
Eton Pharmaceuticals Acquires U.S. Commercialization Rights to Hemangeol From Pierre Fabre
Eton Pharmaceuticals announced it has in‑licensed the U.S. commercialization rights to Hemangeol®, the only FDA‑approved treatment for infantile hemangioma, from Pierre Fabre Medicament Sas. The acquisition, disclosed in early March 2026, will be financed with cash on hand and is...
Cigna Acquires CarepathRx to Expand Hospital Pharmacy Services
Cigna announced the acquisition of CarepathRx, a private‑equity‑backed pharmacy that supplies prescription drugs to roughly 10% of U.S. hospitals. The deal expands Cigna’s vertical integration in the pharmaceutical supply chain, complementing its earlier purchase of Express Scripts.
Asahi Kasei to Acquire German Biotech Aicuris for €780M
Japanese drugmaker Asahi Kasei announced it will acquire German biotech Aicuris for €780 million, gaining its antiviral therapy pritelivir targeting HSV. The deal expands Asahi Kasei's anti‑infectives portfolio and supports its goal of reaching JPY 300 billion in pharma sales by 2030.
